Effect of stellate ganglion block on perioperative myocardial injury following thoracoscopic surgery for lung cancer (SGBMI): protocol for a single-centre, randomised controlled trial Authors: Wei Wu, Haofei Dai, Meiyun Liu, Yang Liu, Hong Shi Published: 2024 ABSTRACT AbstractIntroductionMyocardial injury is a common complication of thoracoscopic surgery. The stellate ganglion block is believed to affect myocardial oxygen consumption. The Stellate Ganglion Block and Myocardial Injury (SGBMI) trial aims to test the hypothesis that stellate ganglion block can reduce the incidence of perioperative myocardial injury in patients undergoing thoracoscopic surgery for lung cancer.Methods and analysisThe SGBMI trial is a double-blind, randomised trial comparing the effects of a stellate ganglion block and a sham procedure in patients with cardiovascular risk factors undergoing thoracoscopic surgery. The exclusion criteria include procedure-related contraindications and severe heart failure. The stellate ganglion block or sham procedures will be performed preoperatively. The primary outcome is myocardial injury within 30 days of the follow-up. The main safety outcomes are sepsis, infection and procedure-related complications. We will enrol 248 patients to ensure at least 80% power for the evaluation of the primary outcome. The primary results of the SGBMI trial are expected to be announced by the year 2027.Ethics and disseminationEthical approval for the study is obtained from the Ethics Committee of the Shanghai Pulmonary Hospital (approval number: L22-394). Written informed consent will be obtained from all participating patients. The publication of results in a peer-reviewed journal and presentations at conferences are anticipated.Trial registration numberChiCTR2300071469 (registered on 16 May 2023). WHAT IS ALREADY KNOWN ON THIS TOPIC WHAT THIS STUDY ADDS To the best of our knowledge, this study is the first randomised controlled trial that evaluates the efficacy of stellate ganglion block in preventing perioperative myocardial injury in patients undergoing thoracoscopic lung resection. To the best of our knowledge, this study is the first randomised controlled trial that evaluates the efficacy of stellate ganglion block in preventing perioperative myocardial injury in patients undergoing thoracoscopic lung resection. HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY Findings from this study are expected to provide high-level evidence in the field of myocardial injury. If our research hypothesis is validated, it could introduce an easily implementable and effective preventive measure for postoperative myocardial injury, potentially influencing clinical practices and healthcare policies. Findings from this study are expected to provide high-level evidence in the field of myocardial injury. If our research hypothesis is validated, it could introduce an easily implementable and effective preventive measure for postoperative myocardial injury, potentially influencing clinical practices and healthcare policies. Introduction Thoracoscopic lung resection is a well-established and widely employed surgical procedure for managing lung cancer.1 The increasing popularity of thoracoscopic lung resection is attributed to its benefits, such as reduced surgical trauma, faster recovery time, improved work reintegration and superior cosmetic outcomes.2 3 Nevertheless, the impact of the procedure on cardiovascular function is noteworthy, particularly concerning the elevated right ventricular afterload that persists during and after thoracoscopic lung surgery.4 This persistent increase in right ventricular afterload may lead to sustained right ventricular dysfunction in patients undergoing lung resection,5 potentially triggering a cascade of cardiovascular complications, including myocardial injury and atrial fibrillation, throughout the postoperative period.6 Perioperative myocardial infarction (MI)/injury is defined as acute cardiomyocyte injury (postoperative hs-cTn T/I release) with or without accompanying symptoms and with or without ECG or imaging evidence of acute myocardial ischaemia.7In thoracic surgery, myocardial injury is quite common, occurring in 19.8% of cases.8 Myocardial injury may be attributable to ischaemic or non-ischaemic causes.9 10 Myocardial injury is typically asymptomatic, with only 6% of patients experiencing chest pain, which is markedly different from spontaneous MI.11 Additionally, in patients undergoing thoracic surgery, detection and diagnosis are particularly challenging owing to the presence of postoperative chest pain.12 This condition may progress to major adverse cardiac events (MACE), leading to a notable extension of hospitalisation and exacerbating the economic burden on healthcare resources.13 Myocardial injury is associated with substantial 30-day and 1-year mortality rates of 9% and 22%, respectively.11 Based on a comprehensive understanding of the anatomy and physiology of the autonomic nervous system and its role in the cardiovascular system, a range of autonomic neuromodulation therapies have been implemented for perioperative diagnosis and treatment, with stellate ganglion block (SGB) being one of them.14 SGB induces sympathetic nerve blockade by administering local anaesthetics into nerve bundles in the cervical area.15 This intervention influences various factors contributing to increased myocardial oxygen consumption during the perioperative period, thereby addressing the balance between myocardial oxygen supply and demand.1619 Preoperative SGB plays a crucial role in maintaining haemodynamic stability during anaesthesia induction, endotracheal intubation and pneumoperitoneum.18 Additionally, studies have shown that SGB can effectively alleviate postoperative pain.19 To the best of our knowledge, in the literature, there is no research on the impact of SGB on myocardial injury after thoracoscopic surgery. Hence, we plan to conduct a randomised controlled study to investigate whether preoperative SGB can reduce the incidence of postoperative myocardial injury in patients with cardiovascular risk factors undergoing thoracoscopic lung surgery. Methods and analysis Patient and public involvement Patients and/or the public were not involved in the design, conduct, reporting or dissemination plans of this research. Design The Stellate Ganglion Block and Myocardial Injury (SGBMI) trial will be a prospective double-blinded, single-centre, parallel-group, randomised controlled trial conducted at the Shanghai Pulmonary Hospital. The flow diagram of the study is illustrated in figure 1. The study design adhered to the guidelines outlined in the Standard Protocol Items for Randomised Trials (SPIRIT), with the SPIRIT checklist provided in online supplemental file 1. Ethical approval for this study was granted by the Ethics Committee of Shanghai Pulmonary Hospital (approval number L22-394). Additionally, this trial was prospectively registered in the Chinese Clinical Trial Registry on 16 May 2023 (ChiCTR2300071469). Study flow chart. SGB, stellate ganglion block. The primary aim of this trial is to investigate whether SGB can significantly reduce the incidence of myocardial injury in patients undergoing thoracoscopic surgery with pre-existing cardiovascular risk factors. Participants The SGBMI aims to enrol 248 patients and follow them for 60 days. All patients scheduled for thoracoscopic surgery for suspected or confirmed lung cancer will undergo eligibility screening 1 day before the scheduled operation. Eligible patients will be enrolled in our study, during which we will provide detailed research information. Before patients are enrolled in our study, informed consent will be obtained from each patient or their legally authorised representative. No study procedure will begin until informed consent is obtained. Patients will be informed of their right to withdraw from the trial at any time, without the need to provide a reason, and assured that this decision will not affect their future care. Recruitment Participants will be recruited at Shanghai Pulmonary Hospital in Shanghai, China. Participants will be screened for eligibility prior to enrolment. Enrolment into the trial and subsequent baseline measurement will occur before surgery. The enrolment schedule is shown in figure 2. SPIRIT figure: schedule of enrolment, interventions and assessments. POD, postoperative day; SPIRIT, Standard Protocol Items: Recommendations for Interventional Trials. The inclusion and exclusion criteria are listed in table 1. Eligible patients must have significant cardiovascular risk factors, be aged 45 years or older, and be scheduled for elective or emergent surgery under general anaesthesia with an anticipated duration of 1 hour or more. Exclusion criteria included contraindications to the SGB procedure, severe heart failure, and the use of positive inotropic agents. The detailed definitions of the inclusion and exclusion criteria can be found in online supplemental file 1. Table 1Eligibility criteriaInclusion criteriaAll of the specified criteria (1–4) must be met. Age 45 years or above. Elective or emergent surgery under general anaesthesia. Scheduled for video-assisted thoracoscopic lung surgery with an expected duration of 1 hour or more. Meet any one of the following four criteria:History of coronary artery disease, including angina.History of stroke.History of peripheral arterial disease.Any two of the following eight criteria:Emergent surgery.Current or prior daily smoking.History of hypertension.Diabetes mellitus requiring medical treatment.History of transient cerebral ischaemia.Plasma creatinine >175 µM.Age 70 years or above.History of congestive heart failure. Exclusion criteria Coagulation disorders. Localised skin infection. Glaucoma. Thyroid disorders. Cardiac conduction abnormalities. Patients with psychiatric disorders unable to cooperate. Pregnant women (a routine HCG will not be measured if women are 50 years or older). Absence of preoperative informed consent or refusal to participate. Allergy to investigational drugs used in the trial. Septicaemia. Preoperative treatment with positive inotropic agents. Severe heart failure (defined as ejection fraction <30%). Acute cardiac conditions. Eligibility criteria Randomisation and blinding Eligible patients providing written informed consent will be randomly assigned in a 1:1 ratio to either the SGB group or the sham procedure group prior to surgery. The randomisation schedule, prepared by a biostatistician, will be stratified by surgical type using blocks of six. To ensure allocation concealment, access to the schedule will be restricted to a researcher not involved in participant recruitment, scheduling or assessment, who will access it through a password-protected computer programme. In this study, a seasoned operator specialising in SGB will exclusively perform all interventions, avoiding involvement in additional clinical care. Owing to the nature of the procedure, the blinding of the operator is not feasible. However, other medical team members, including the surgeons, anaesthesiologists and postoperative medical management team, will remain unaware of the patient’s group assignment. Patients will wear an eye mask postintervention to prevent the manifestation of Horner’s syndrome (ptosis, miosis and scleral injection), which will be monitored by a medical team. The patients will remain uninformed about the specific procedure. An observer, strictly blinded to the group assignment, will assess the complications during hospitalisation and postoperative follow-up. Additionally, the statistical analysis expert overseeing the study results will remain uninformed of groupings, designated as group A and group B. Procedure and interventions Standard anaesthetic and analgesic management We will conduct standardised monitoring for all patients on arrival at the operating theatre, including ECG, blood pressure and peripheral oxygen saturation (SpO2). Before anaesthesia induction, an intravenous catheter will be routinely inserted into the right internal jugular vein. Anaesthesia induction will commence with midazolam (0.05 mg/kg), propofol (1–2 mg/kg), sufentanil (0.5–0.7 µg/kg) and 0.6 mg/kg rocuronium bromide. Subsequently, double-lumen tracheal intubation will be performed for mechanical ventilation. Ventilation will adhere to a one-lung protective approach, using tidal volumes of 6 mL/kg or lower, based on the predicted body weight and a positive end-expiratory pressure of 5–10 cm H2O, following the established guidelines and expert recommendations.20 The respiratory rate will be adjusted to maintain the end-tidal carbon dioxide levels within the range of 35–45 mm Hg. Anaesthesia maintenance postintubation with a double-lumen endotracheal tube will involve administering propofol and remifentanil to achieve a spectral entropy value between 40 and 60. Postoperative pain management strictly adhered to a standardised protocol. This will include administering 5 µg of sufentanil and a 50 mg intravenous infusion of flurbiprofen axetil 30 min before the conclusion of the surgery. Patients will also receive a daily intravenous infusion of 50 mg flurbiprofen axetil as postoperative analgesia. Patient-controlled analgesia will use a 24-hour infusion of sufentanil at a concentration of 1 µg/mL solution, with an infusion rate of 2 mL/hour, a 2 mL bolus dose, a 15-min lockout time and a maximum limit of 10 mL/hour. Patient-controlled analgesia treatment will commence based on a numerical rating scale score >2. Oxycodone (5 mg/acetaminophen 325 mg) is available as a rescue analgesic. There will be no restrictions or prohibitions on medical care and therapeutics during the hospital stay on enrolment. Intervention In the sham procedure, patients will be positioned supine. Following standard antiseptic preparation and draping, a high-frequency ultrasound transducer probe (L38Xi, Sonosite, USA) will be used to visualise the anatomical structures at the C6 and C7 vertebral levels. No additional interventions will be conducted. In the active SGB arm, patients will be assigned to receive the right SGB under ultrasound guidance. Patients will lie supine with a slightly extended neck, and a high-frequency ultrasound transducer probe (L38Xi, Sonosite, USA) will be positioned transversely at the C7 level. Ultrasound visualises the neck anatomy at C7, which is identified by the absence of the anterior tubercle. Lateral scanning will identify the internal jugular vein, common carotid artery and longus colli muscles. Colour Doppler imaging can prevent the penetration of blood vessels. At the C6 level, a 22-gauge needle (001156–71, PAJUNK, USA) will be laterally inserted, with the needle tip positioned posterior to the carotid artery and anterior to the longus colli muscle using an in-plane approach (figure 3).21 Subsequently, a single 5 mL dose of 0.5% ropivacaine will be administered to the stellate ganglion after confirming the absence of blood through negative aspiration. Puncture path at the level of the C6 transverse process. ATTP, anterior tubercle of transverse process; CA, carotid artery; IJV, internal jugular vein; LCM, long neck muscle; PTTP, posterior tubercle of transverse process; SCM, sternocleidomastoid muscle; triangle indicates the stellate ganglion block area; arrow indicates the simulated puncture path. Follow-up The patients will undergo monitoring two times per day throughout their hospitalisation until discharge. Patients will undergo blood collection on the day before surgery and on the first, second and third days postoperatively, contingent on the duration of their hospital stay. Troponin levels will be measured using the Roche fifth-generation Elecsys hsTnT assay, which has a manufacturer-specified 99th percentile upper reference limit (URL) of 14 ng/L. Outcome ascertainment will closely adhere to standard clinical practices, acknowledging the potential to overlook specific asymptomatic postdischarge events. Previous research has highlighted that the majority of myocardial injury events occur within the first 3 days after surgery. Additionally, patients will have follow-up assessments on days 14, 30 and 60 after postrandomisation. The 14th-day assessment will be in-person at the clinic, and the assessments on the 30th and 60th days will be conducted via telephone. Outcome measures The primary objective of this trial is to evaluate whether SGB, compared with a sham procedure, reduces the occurrence of myocardial injury in patients with elevated cardiovascular risk factors within 30 days of randomisation. The primary outcome is myocardial injury, defined as any MI and any elevated troponin level (exceeding the URL), deemed to be attributable to myocardial ischaemia, occurring within the first 30 days after the initiation of surgery. The secondary objective of the trial is to assess whether SGB, in comparison to a sham procedure, reduces the following outcomes within 60 days after randomisation: All-cause mortality rates at 30 and 60 days; All-cause mortality rates at 30 and 60 days; Acute kidney injury (defined by the Kidney Disease Improving Global Outcomes criteria); Acute kidney injury (defined by the Kidney Disease Improving Global Outcomes criteria); Delirium and Postoperative sleep disturbance; Delirium and Postoperative sleep disturbance; MI; MI; MACE; MACE; Hospitalisation duration and readmission rates; Hospitalisation duration and readmission rates; Improvement in postoperative recovery quality. Improvement in postoperative recovery quality. The safety outcomes are outlined as follows: Composite of sepsis or infection; Composite of sepsis or infection; Procedure-related complications. Procedure-related complications. The adjudication committee comprises clinicians with expertise in perioperative outcomes. Unaware of treatment allocations, this committee assesses the primary endpoints and other outcomes based on a predefined adjudication plan. The determinations made by outcome adjudicators will serve as the basis for all statistical analyses related to these events. Detailed definitions of all the outcome events are provided in online supplemental file 1. Sample size calculations The sample size estimation is based on findings from our preliminary, unpublished pilot study, which involved 47 patients and was conducted between June and October 2022. In this initial investigation, the incidence rates of postoperative myocardial injury in the SGB and sham groups were 16% (4/25) and 31.82% (7/22), respectively. Considering an estimated dropout rate of 10%, we calculated the required sample size of 248 patients (124 per group). This size is sufficient to detect a 50% reduction in the incidence rates of postoperative myocardial injury among patients undergoing SGB compared with a sham procedure, with a statistical power of 80% at a significance level of 0.05. Statistical analysis Before initiating the statistical analysis of the trial, we will develop a comprehensive statistical analysis plan in accordance with the principles outlined in this section. This plan will be established before the trial’s conclusion and unblinding process, ensuring a systematic and well-defined approach. After completing the trial, all statistical analyses will conform to the established statistical analysis plan, which will be drafted before the trial concludes, thereby providing a clear framework for the analysis process. Statistical software packages, including Stata and R, will be used for the data analysis. All tests will be two-sided, and statistical significance will be determined with a threshold of a p value <0.05. We will address the missing data, and appropriate implications will be discussed and implemented as necessary. Categorical data will be presented in terms of frequency and percentage, while continuous data will be reported as mean and SD or median and IQR. For the analysis of primary and secondary endpoints, we will employ both univariate and multivariate regression models, with a preference for adjusted analyses as the primary approach. Cumulative incidence curves will be generated for the two treatment groups for primary outcomes, and log-rank tests will be used for comparison. Cox proportional hazard models, with the treatment group as an independent variable and adjustments for clinically relevant confounders, will be used to derive HRs, 95% CIs and p values. Regarding all secondary or safety outcomes, mixed-effects regression models will be used to assess the treatment effect. Adjustments will be made for clinically relevant confounders. Data analysis will be conducted in the modified intention-to-treat population, encompassing all patients undergoing randomisation and undergoing a procedure. The prespecified subgroups for outcomes will include sex, age and type of surgery. Given the variations in missing data mechanisms, sensitivity analyses for the primary endpoint will be performed to evaluate the robustness of our estimates against different imputation models. Data collection and management Data will be securely stored in compliance with Good Clinical Practice standards. The research team will meticulously extract preoperative, intraoperative and postoperative follow-up data from the electronic medical records, monitoring devices, and relevant manual records. The collected data will undergo meticulous curation using the EpiData database hosted at the anaesthesiology centre of Shanghai Pulmonary Hospital. The Data Safety and Monitoring Board (DSMB) will comprise two senior anaesthesiologists and one surgeon, all of whom will be blinded status with regard to the study. This independent DSMB will diligently oversee patient safety and have access to unblinded data. The Clinical Research Centre at Shanghai Pulmonary Hospital will assume responsibility for site management, monitoring, and data cleaning. Trial status The first SGBMI patient was randomised on 6 September 2023. As of 29 February 2024, 25 patients have been enrolled in the study. The latest version of the reported protocol is the 202210VR4. Ethics and dissemination Ethics approval This study was approved by the Ethics Committee of Shanghai Pulmonary Hospital (approval number L22-394). Informed consent will be mandatory for all participating patients. All protocol changes will be submitted for ethics approval and amended on the registry. Study will be conducted according to the Declaration of Helsinki and the International Conference on Harmonisation Good Clinical Practice guidelines. Dissemination All the data will be anonymised and aggregated for presentation and publication. Following the completion of the data collection and analysis, a manuscript detailing the effects of the intervention will be submitted to a peer-reviewed journal. No participants will be identified in any of the publications resulting from this study. supplementary material